SCHEMBL29398972

SCHEMBL29398972

CCc1ccc(Nc2c(C)cc(Cl)cc2Cl)c(CC(=O)O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 9/20 0.66
CAMK2A Q9UQM7 3/20 0.49
ABCB11 O95342 2/20 0.48
PTGS1 P23219 2/20 0.48
NR1I3 Q14994 2/20 0.48
PPARG P37231 1/20 0.48
CXCL8 P10145 3/20 0.46
CLIC1 O00299 1/20 0.46
CLCN2 P51788 1/20 0.46
TTR P02766 2/20 0.43
AKR1B10 O60218 1/20 0.43
UGT1A9 O60656 1/20 0.43
TRPA1 O75762 1/20 0.43
MT-CO2 P00403 1/20 0.43
ALB P02768 1/20 0.43
UGT1A6 P19224 1/20 0.43
UGT1A1 P22309 1/20 0.43
CXCR1 P25024 1/20 0.43
ADRA1A P35348 1/20 0.43
AGTR2 P50052 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1030956 1.00 PTGS2 (0.66) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL1028714 0.88 PTGS2 (0.54) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL1032830 0.88 PTGS2 (0.54) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL6036173 0.88 PTGS2 (0.52) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL1032831 0.87 PTGS2 (0.61) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL2070703 0.86 PTGS2 (0.88) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL1031824 0.86 PTGS2 (0.76) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL6036623 0.83 PTGS2 (0.72) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL27752715 0.81 PTGS2 (0.55) PTGS2CAMK2AABCB11PTGS1NR1I3
SCHEMBL1032030 0.80 PTGS2 (0.56) PTGS2CAMK2AABCB11PTGS1NR1I3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3956025-A1 CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO Allergan Sales, LLC (US) 2022-02-23 EP claimed
EP-4263571-A1 COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS Pfizer Ireland Pharmaceuticals (IE) 2023-10-25 EP disclosed
EP-4247364-A1 COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS Pfizer Ireland Pharmaceuticals (IE) 2023-09-27 EP disclosed
CN-116456981-A Compositions for improved GRP inhibitor delivery 辉瑞爱尔兰制药公司 2023-07-18 CN disclosed
EP-4076395-A1 INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS Biohaven Pharmaceutical Holding Company Ltd. (US) 2022-10-26 EP disclosed
CN-114980862-A Intranasal pharmaceutical compositions of CGRP inhibitors 拜尔哈文制药股份有限公司 2022-08-30 CN disclosed
WO-2022165291-A1 PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2022-08-04 WO disclosed
EP-4034156-A1 COMBINATION THERAPY WITH CGRP ANTAGONISTS Allergan Pharmaceuticals International Limited (IE) 2022-08-03 EP disclosed
WO-2022132989-A1 COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2022-06-23 WO disclosed
WO-2022109077-A1 COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2022-05-27 WO disclosed
EP-3956025-A1 CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO Allergan Sales, LLC (US) 2022-02-23 EP disclosed